Mediterranean diet, cardiovascular disease and mortality in diabetes: a systematic review and meta-analysis of prospective cohort studies and randomized clinical trials

Nerea Becerra-Tomás,[a,b,c,d] Sonia Blanco Mejía,[e,f] Effie Viguiliouk,[e,f] Tauseef Khan,[e,f] Cyril W Kendall,[e,f,g] Hana Kahleova,[h,i] Dario Rahelić,[j,k] John L Sievenpiper,[e,f,l] and Jordi Salas-Salvadó[a,b,c,d]

[a]Universitat Rovira i Virgili, Departament de Bioquímica i Biotecnologia, Unitat de Nutrició, Reus, Spain

[b]Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain

[c]Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, Madrid, Spain

[d]University Hospital of Sant Joan de Reus, Nutrition Unit, Reus, Spain

[e]Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

[f]Toronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada

[g]College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

[h]Institute for Clinical and Experimental Medicine, Prague, Czech Republic

[i]Physicians Committee for Responsible Medicine, Washington, DC, USA

[j] Department of Endocrinology, Diabetes and Clinical Pharmacology Dubrava University Hospital, Zagreb, Croatia

[k] School of Medicine, University of Zagreb

[l] Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada

Corresponding author/request for reprints: Prof. Jordi Salas-Salvadó, MD, PhD. Human Nutrition Unit, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili. C/ Sant Llorenç 21, 43201 Reus (Spain). Telephone number: +34 977759312; Fax number: +34 977759322; e-mail address: jordi.salas@urv.cat

Running title: Mediterranean diet, cardiovascular disease and mortality.

Abstract word count: 363

Main text word count: 5,343

Number of tables: 2

Number of figures: 2

Electronic supplementary material: Supplemental figures 1-31, Supplemental tables 1-4

References: 73

ABSTRACT

Objectives: To update the clinical practice guidelines for nutrition therapy of the European Association for the Study of Diabetes (EASD) , we conducted a systematic review and meta-analysis of prospective cohort studies and randomized clinical trials (RCTs) to evaluate the effect of the Mediterranean diet (MedDiet) on the prevention of cardiovascular disease (CVD) incidence and mortality.

Methods: Medline, EMBASE (through April 20, 2018) and Cochrane (through May 7, 2018) databases were searched. We included prospective cohort studies and RCTs evaluating the MedDiet in relation to the incidence of, or mortality from, CVD outcomes in populations that included individuals with diabetes. Outcomes included incidence of and mortality from total CVD, coronary heart disease (CHD), stroke and myocardial infarction (MI). Two independent reviewers extracted relevant data and assessed risk of bias. We conducted two separate meta-analyses, one for RCTs and another for prospective cohort studies. Data were pooled by the generic inverse variance method and expressed as relative risk (RR) and 95% confidence interval (CI). Heterogeneity was tested by the Cochrane Q statistic and quantified by the I^2-statistic. The certainty of the evidence was assessed by the GRADE tool.

Results: A total of 41 reports (3 RCTs and 38 cohorts) were included. Meta-analyses of RCTs revealed a beneficial effect of the MedDiet on total CVD incidence (RR: 0.62; 95% CI: 0.50, 0.78) and total MI incidence (RR: 0.65; 95% CI: 0.49, 0.88). There was no effect on CVD mortality. No meta-analysis could be performed for the other outcomes (CHD incidence, CHD mortality, stroke incidence, stroke Mortality and MI mortality). Meta-analyses of prospective cohort studies, which compared the highest *vs* lowest categories of MedDiet adherence, revealed an inverse association with total CVD mortality (RR: 0.79; 95% CI: 0.77, 0.82), CHD incidence (RR: 0.73; 95% CI: 0.62, 0.86), CHD mortality (RR: 0.83; 95% CI: 0.75, 0.92), stroke incidence (RR: 0.80; 95% CI: 0.71, 0.90), stroke

mortality (RR: 0.87; 95% CI: 0.80, 0.96) and MI incidence (RR: 0.73; 95% CI: 0.61, 0.88). The overall certainty of the evidence across outcomes ranged from very low to moderate.

Conclusions: The present study suggests that MedDiet has a beneficial role on CVD prevention in populations inclusive of individuals with diabetes.

Key words: Mediterranean diet, cardiovascular disease, cardiovascular mortality, diabetes, meta-analysis

BACKGROUND

Cardiovascular diseases (CVDs) are considered to be the leading cause of mortality worldwide, accounting for 31% of all global deaths in 2015 (1). Data from epidemiological studies suggest that diabetes is an important predisposing factor for CVD risk. In fact, a collaborative meta-analysis of 97 prospective studies revealed that individuals with diabetes had a approximately a two-fold higher risk of coronary heart disease (CHD), stroke and vascular death, than their counterparts without the disease (2). CVDs are largely preventable by managing modifiable adverse behaviors, such as an unhealthy diet, unhealthy body weight tobacco use or physical inactivity (3). Therefore, promoting healthy lifestyles should be an important strategy to reduce CVD burden not only in people with type 2 diabetes (T2D) but also in the general population. In this regard, the traditional Mediterranean diet (MedDiet), which is rich in vegetables, fruits, extra-virgin olive oil, nuts, legumes and whole grains, and low to moderate in animal products, has been identified as one of the healthiest dietary patterns for CVD prevention (4).

To date, several meta-analyses of observational studies (5–9) and clinical trials (6,7,10) analyzing MedDiet and the risk of incidence of or mortality from total or different types of CVDs support these beneficial effects. It is noteworthy that only one meta-analysis evaluated prospective cohort studies and randomized clinical trials (RCT) (7) of the association of MedDiet with CVD, however, it did not report on individual causes of CVD mortality, such as stroke, CHD and myocardial infarction (MI). Moreover, despite the fact that diabetes confers a higher risk of CVDs, no previous meta-analyses took this into consideration when defining their study population. Therefore, there is a gap in knowledge for the value of the MedDiet in preventing CVD in individuals with diabetes. The clinical practice guidelines for nutrition therapy of the European Association for the

Study of Diabetes (EASD) have made no specific recommendations regarding the MedDiet. Therefore, in order to develop evidence-based recommendations, the Diabetes and Nutrition Study group (DNSG) of the EASD commissioned a systematic review and meta-analysis (SRMA) of prospective cohort studies and RCTs using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system to summarize the evidence available on the relationship of MedDiet with total CVD, CHD, stroke and MI incidence and mortality in populations inclusive of individuals with diabetes.

METHODS

The present SRMA was conducted in accordance with the Cochrane handbook for systematic reviews of interventions (11), and results were reported in accordance with Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines (12). The study protocol is available at https://www.crd.york.ac.uk/PROSPERO/ (number of registration: CRD42017057885).

SEARCH STRATEGY AND DATA SOURCES

A comprehensive search, which was limited to human studies without language restrictions, was performed through January 16, 2017 in MEDLINE and EMBASE databases and through February 9, 2017 in the Cochrane Library database. We updated searches in April 20, 2018 and in May 7, 2018, respectively. The complete search strategy is presented in **Supplementary Table 1**. A manual review of articles' reference lists supplemented the electronic search. We also contacted subject experts for a list of articles on the subject.

STUDY SELECTION

All titles and abstracts were initially screened to assess the eligibility criteria. We only included prospective cohort studies and RCTs with a study population that included adults with type 1 diabetes or T2D; ≥ 1 year of follow-up; MedDiet as exposure (assessed by indexes or scores in the case of prospective cohort studies); and incidence of or mortality from CVD, CHD, MI and stroke as outcome. When more than one article from the same study was identified, we included both papers if the reported outcomes were different (i.e. CHD in one and total CVD in the other one). When multiple articles conducted in the same study population reported the same outcome, the one with the longest follow-up was selected. We did not include published abstracts.

For the PREDIMED trial, the original paper (13) was withdrawn and republished in June 2018 (14) because some deviations from the protocol randomization procedure were detected. Therefore, although our search strategy did not identify this new publication, we felt that it was appropriate to include in the meta-analysis the results of the new report, which were similar to the findings originally reported.

DATA EXTRACTION

Two independent researchers (NB-T and EV) reviewed the full text of the articles that passed the first screening. A standardized *proforma* was used to extract relevant information including: year of publication, country, characteristics of the participants, study setting, sample size, follow-up duration, outcome assessment, MedDiet assessment method (only in cohort studies), sources of funding, number of incident cases, covariates used for adjustments of the statistical analyses, and effect estimators (risk ratios, odds ratios, hazard ratios) and 95% CIs of CVD, CHD, MI, stroke incidence and mortality per quantiles of MedDiet adherence (in the case of prospective cohort studies) and for intervention arms (in RCTs). If necessary, authors were contacted by email if any

additional information was required. All disagreements were resolved by consensus or by a third author (JLS) when necessary.

STUDY QUALITY

The study quality of prospective cohort studies was assessed using the Newcastle-Ottawa scale (NOS) (15). It consists of a rating scale which gives points to studies in three domains: population selection (maximum of 4 points), outcome assessment (maximum 3 points) and comparability of the groups (maximum 2 points). For the present analysis, those studies that received ≥7 points were considered to be of high quality. The quality of RCTs was assessed with the Cochrane Collaboration Tool (11), which includes five different domains: sequence generation, allocation concealment, blinding, outcome data and outcome reporting. Each domain was judged to have a high, low or unclear risk of bias. Any disagreements were resolved by consensus.

OUTCOMES

For the present systematic review and meta-analysis, eight sets of outcomes were considered: incidence (including non-fatal outcomes or a composite of fatal and non-fatal outcomes) of total CVD; CHD; stroke; MI; and mortality (only including fatal outcomes) from total CVD; CHD; stroke and MI. Studies reporting separate risk estimates for hemorrhagic and ischemic stroke (16,17) were combined within each study using a fixed-effects model to generate an overall estimate for stroke incidence. Similarly, we combined non-fatal and fatal MI (18) within studies to obtain an overall estimate for MI incidence.

STATISTICAL ANALYSES

In order to obtain summary estimates, the RRs, HRs and ORs were natural log-transformed and pooled using the inverse variance method with random-effects model. Fixed–effects model was used if number of comparisons was less than five. Due to the

low incidence of CVD and modest effect sizes, ORs and HRs were treated as RRs(19,20). Only two studies reported the risk estimates as ORs, which were considered equivalent to RRs (21,22). We conducted separate meta-analyses for RCTs and prospective cohort studies.

For the meta-analysis of RCTs, we considered the outcome of total CVD incidence to be the composite end-point including MI, CVD death, episodes of unstable angina, heart failure, stroke and pulmonary or peripheral embolism reported by Lorgeril et al., in the Lyon Diet Heart Study (23). In the PREDIMED study including MI, stroke and death from CVD, we used the HRs reported by both MedDiet intervention groups merged versus the control group (14).

For the primary meta-analysis of prospective cohort studies, we used RRs comparing extreme categories of MedDiet adherence. In those studies in which the highest category was considered to be the reference, the RR and 95% CI was recalculated to make the lowest category as the reference (24).

As a secondary analysis, we took the studies that used different scores and cut-off points to assess MedDiet adherence and estimated the RRs for every 2-point increment in the MedDiet score. When studies did not use the traditional MedDiet score proposed by Trichopoulou et al., ranging from 0 to 9 (25), we re-scaled them to a 9-point scale because it is the most-used score in epidemiological settings. When studies reported the risk for every 2-point increment, we directly used the natural log-transformed risk estimates. For those studies reporting a different point increment, it was transformed as appropriate. For example, if a study reported RRs for 1-point increments, the RRs were calculated by multiplying the natural log-transformed risk estimates by 2. If studies did not report the RRs in a continuous form, we estimated them only when MedDiet adherence was

categorized at least in three categories, following the log-linear dose-response model for a single study (26).

Furthermore, the linear dose-response gradient was also assessed by using generalized least squares trend (GLST) following the method described by Greenland and Longnecker (27) and Orsini (28) when at least three study comparisons were available. Non-linear dose-response association was assessed by using a two-stage multivariate random-effects method using restricted cubic splines with three knots. For this analysis, we included only those studies that reported at least three categories of MedDiet as exposure. We converted to the 9-point scale all those studies that used a different point scale from the traditional one (ranging from 0 to 9). We used the mean or median of each category when it was reported or we calculated the midpoint between the upper and lower bound when ranges were described. For those studies that reported open-ended extreme categories, we assumed the width of the adjacent interval. If a study did not report cases or the total number of participants in each category, we imputed them following the method described by Bekkering and co-workers (29).

For all meta-analyses, inter-study heterogeneity was assessed using the Cochran Q statistic and quantified using the I^2 statistic, where I^2>50% at P_Q<0.10 was considered evidence of substantial heterogeneity (11). Sensitivity analysis was performed by removing one study at a time from the meta-analysis and recalculating the summary risk estimates. We considered a study as influential if removing it changed the magnitude (by >20%), the direction or the significance of the pooled risk estimates, or the evidence of heterogeneity.

A priori and *post-hoc* subgroup analyses were performed using meta-regression when 10 or more comparisons were available *A priori* subgroup analyses included sex (males vs. females vs. mixed), follow-up (< vs. ≥ median), NOS (<7 vs. ≥7) and individual domains

of risk of bias (NOS or The Cochrane Collaboration Tool). A *post-hoc* analyses included MedDiet score assessment (Trichopolou original 9 points vs. adapted from Trichopolou original vs. others) and type of population (Mediterranean vs. non-Mediterranean). If ≥10 comparisons were available, the risk of publication bias was investigated by visually inspecting funnel plots for asymmetry and quantified by Begg's and Egger's tests ($p < 0.05$ was considered significant for small study effects). If there was evidence of publication bias, then we used the Duval and Tweedie trim and fill method to adjust for funnel plot asymmetry by imputing missing study data (30).

All data analysis was performed using the Review Manager (RevMan) version 5.3 and Stata version 15 (StataCorp).

GRADING THE EVIDENCE

The GRADE system was used to rate the certainty and strength of the evidence. According to this system, observational studies start at low-certainty of evidence, whereas RCTs start at high-certainty (31). The certainty of evidence can be downgraded or upgraded on the basis of some prespecified determinants. Criteria to downgrade include limitations of the study design and execution (weight of studies showed risk of bias by NOS (32) or by the Cochrane Collaboration Tool) (33), inconsistency (inter-study heterogeneity that remains unexplained, $I^2 \geq 50\%$ and $p < 0.10$) (34), indirectness (existence of factors that limit the generalizability of the results) (35), imprecision (wide confidence intervals or overlapping with the minimally important difference of 5% (RR 0.95 to 1.05)) (36) and publication bias (evidence of small-study effect) (37). Criteria to upgrade include large magnitude of effect (RR = <2 or <0.5 in the absence of plausible confounders), dose-response gradient, and attenuation by plausible confounding effects (38). Any disagreements were resolved by consensus.

RESULTS

Figure 1 shows the flow of literature and study selection. The literature search yielded 2,592 potential studies for inclusion and one additional study was obtained by making a manual search of the references of the retrieved articles. After duplicate studies had been removed (n=1,144), 1,448 were screened by title and abstract, and 1,323 were excluded. Of the 125 studies reviewed in full, 41 (14,16–18,21–24,39–71) were finally included in the quantitative synthesis.

Randomized clinical trials

Table 1 shows the characteristics of the RCTs included. A total of 3 RCTs were included (14,18,23). The studies were conducted in India, France and Spain and the publication year ranged from 1999 to 2018. The total sample size ranged from 605 to 7,447 with a follow-up ranging from 2 years to 4.8 years. **Supplemental figure 1** shows the assessment of risk of bias according to the Cochrane Risk of Bias tool. Two of the three studies were at unclear risk of bias for random sequence generation and allocation concealment. Risk of bias was high for one study in terms of allocation concealment. For the other three domains, all studies were considered to be at low risk of bias. Furthermore, the study published by Singh et al., appears to have unreliable data, as stated by the editor of the Lancet journal in a letter of expression of concern (72).

Total CVD incidence

Two studies (14,23) with 8,052 participants, including 332 cases, analyzed the effect of the MedDiet on total CVD incidence (**Figure 2 and Supplemental figure 2**). Pooled analysis showed that MedDiet reduced the risk of total CVD incidence by 38% (RR: 0.62; 95%CI: 0.50, 0.78) with evidence of substantial heterogeneity (I^2 = 86%, $p < 0.01$).

Total CVD mortality

Two studies (14,23) with 8,052 participants, including 106 cases, analyzed the effect of the MedDiet on total CVD mortality (**Figure 2 and Supplemental figure 3**). Pooled

analysis showed that the MedDiet did not decrease the risk of total CVD mortality (RR: 0.67; 95%CI: 0.45, 1.00) and there was evidence of substantial heterogeneity between studies (I^2 = 64%, p = 0.09).

CHD incidence

Only one study (18) conducted in 1,000 participants with a previous heart attack or at least one major risk factor for coronary artery disease has analyzed the effect of the MedDiet, specifically an Indo-Mediterranean diet, on risk of CHD incidence (115 cases) (**Figure 2 and Supplemental figure 4**). As a consequence, a meta-analysis could not be undertaken for this outcome. The results of this trial showed that compared to a diet similar to a step I diet of the American Heart Association, the MedDiet significantly reduced the risk of CHD incidence by 52% (RR: 0.48; 95%CI: 0.33, 0.71) (18).

CHD mortality

The study conducted by Sing et al. (18) (1,000 participants, 22 cases) is the only randomized clinical trial that has evaluated the effect of an Indo-Mediterranean diet on the risk of CHD mortality. Therefore, we could not undertake a meta-analysis for this outcome (**Figure 2 and Supplemental figure 5**). The results of the clinical trial showed that the individuals in the intervention group had a 67% lower risk of sudden cardiac death than those in the control group (RR: 0.33, 95%CI: 0.13, 0.86) after 2 years of follow-up.

Stroke incidence

To date only one RCT (14) has evaluated the effect of the MedDiet on stroke prevention. The study was a multicenter parallel group clinical trial conducted in 7,447 elderly Spanish individuals at high risk of CVD (139 cases). The results showed that the two MedDiet intervention groups (one enriched with extra virgin olive oil and the other with a mix of nuts) had a 42% lower risk of stroke incidence than the control group on a low-

fat diet, (RR: 0.58; 95%CI: 0.42, 0.81). Because only one trial comparison was available, we did not conduct a meta-analysis for this outcome (**Figure 2 and Supplemental figure 6**).

Stroke mortality

We did not identify any RCTs analyzing the effect of the MedDiet on stroke mortality risk (**Figure 2**).

MI incidence

Two studies (14,18) with 8,447 participants, including 199 cases, analyzed the effect of the MedDiet on MI incidence (**Figure 2 and Supplemental figure 7**). Pooled analysis showed that the MedDiet significantly decreased the risk of MI by 35% (RR: 0.65; 95%CI: 0.49, 0.88) with no evidence of substantial heterogeneity (I^2 = 50%, p = 0.16).

MI mortality

Only one study (18) conducted in 1,000 participants with myocardial infarction, angina pectoris or risk factors for coronary artery disease sought to evaluate the effect of the MedDiet on MI mortality. After 2 years of follow-up, 29 new cases occurred. Compared to those on the control diet, the individuals in the Indo-Mediterranean diet intervention group had a non-significant trend toward lower risk of MI mortality (RR: 0.67; 95%CI: 0.31, 1.43). A meta-analysis was not undertaken for MI mortality because only one trial comparison was identified (**Figure 2 and Supplemental figure 8**).

Prospective cohort studies

Table 2 shows the characteristics of the prospective cohort studies. Studies were conducted in USA (n=15), Europe (n=20), Australia (n=1), Asia (n=1) and internationally level (n=1) and publication year ranged from 2009 to 2018. The total sample size ranged from 274 to 193,527 participants and the length of follow-up ranged from 2 years to 26

years. According to the NOS scale, 70% of studies were of high quality (**Supplemental table 2**).

Total CVD incidence

Eight cohort comparisons(21,42,47,58,61,62,66,71) with 53,508 participants, including 9,758 events, analyzed the association between MedDiet adherence and the risk of total CVD incidence (**Figure 2 and Supplemental figure 9**). Comparing highest *versus* lowest categories of adherence, the summary pooled risk estimate showed a non-significant inverse association (RR: 0.88; 95%CI: 0.74, 1.04), with evidence of substantial heterogeneity (I^2 = 53%; p = 0.04). The continuous analysis shows that a 2-point increment in the MedDiet score was associated with a 10% lower risk of total CVD incidence (RR: 0.90; 95%CI: 0.85, 0.96), and there was also substantial evidence of inter-study heterogeneity (I^2 = 70%; p < 0.01) (**Supplemental figure 10**).

Total CVD mortality

Twenty-one cohort comparisons (38,40,45,48–51,54,55,60–62,65–68), with 883,878 participants, including 54,728 cases, analyzed the association between MedDiet adherence and the risk of total CVD mortality. There was a significant inverse association (RR: 0.79; 0.77, 0.82) with no evidence of heterogeneity between studies (I^2 = 0%; p = 0.64) when the highest categories were compared with the lowest (**Figure 2 and Supplemental figure 11**). Along the same lines, continuous analysis showed that a 2-point increment in the MedDiet score was associated with a 9% lower risk of total CVD mortality (RR: 0.91; 95%CI: 0.87, 0.96) and there was evidence of substantial heterogeneity (I^2= 95%; p < 0.01) (**supplemental figure 12**).

CHD incidence

Seven cohort comparisons (39,43,44,47,49) with 88,632 participants, including 2,045 cases have analyzed the association between MedDiet adherence and the risk of CHD

incidence. There was a 27% lower risk of total CHD between the highest and lowest categories of adherence (RR: 0.73; 95%CI: 0.62, 0.86), and there was no evidence of inter-study heterogeneity (I^2 =26%, p = 0.23) (**Figure 2 and Supplemental figure 13**). Along the same lines, in the continuous analysis (**Supplemental figure 14**), each 2-point increment in the MedDiet score was associated with a 20% lower risk of CHD incidence (RR: 0.80; 95%CI: 0.76, 0.85) and there was a high degree of inter-study heterogeneity (I^2 = 90%, p < 0.001).

CHD mortality

Six cohort comparisons(41,44,48,67,70) with 270,565 participants, including 2,019 cases, have analyzed the association between MedDiet adherence and the risk of CHD mortality. There was a significant inverse association (RR: 0.73; 95%CI: 0.59, 0.89) and evidence of substantial inter-study heterogeneity (I^2= 63%; p = 0.02) when the highest categories were compared with the lowest (**Figure 2 and Supplemental figure 15**). The continuous analysis showed a significant inverse association for each 2-point increment in the MedDiet score and the risk of CHD mortality (RR: 0.94; 95%CI: 0.91, 0.97), as well as evidence of substantial heterogeneity (I^2 = 76%; p < 0.01) (**supplemental figure 16**).

Stroke incidence

Five cohort comparisons (16,17,42,45) with 73,287 participants, including 2,663 cases, have analyzed the association between MedDiet adherence and the risk of stroke incidence. There was a significant inverse association (RR: 0.80; 95% CI: 0.71, 0.90) and no evidence of heterogeneity between studies (I^2= 0%; p = 0.63) when the highest catergories were compared with the lowest (**Figure 2 and Supplemental figure 17**). The continuous analysis showed that a 2-point increment in the MedDiet score was associated

with a 10% lower risk of stroke incidence (RR: 0.90; 95%CI: 0.85, 0.96) and there was no evidence of inter-study heterogeneity (I^2 = 35%; p = 0.13) (**Supplemental figure 18**).

Stroke mortality

Four cohort comparisons(24,45) with 195,644 participants, including 3,744 cases, have analyzed the association between MedDiet adherence and the risk of stroke mortality. There was a 13% lower risk of stroke mortality (RR: 0.87; 95% CI: 0.80, 0.96) and no evidence of heterogeneity (I^2 =0%, p = 0. 74) when highest categories of adherence to MedDiet were compared with the lowest (**Figure 2 and Supplemental figure 19**). The continuous analysis showed that a 2-point increment in MedDiet adherence was non-significantly inversely associated with the risk of stroke mortality (RR: 0.96; 95% CI: 0.89, 1.04) and there was no evidence of inter-study heterogeneity (I^2=0%, p = 0.86) (**Supplemental figure 20**).

MI incidence

Two cohort comparisons(17,42) have analyzed the association between MedDiet adherence and the risk of MI incidence, including 35,489 participants and 1,242 cases. A comparison of the highest and the lowest categories of adherence to the MedDiet showed a 27% lower risk of total MI (RR: 0.73, 95%CI: 0.61, 0.88) and no evidence of heterogeneity (I^2 = 0%, p = 0.66) (**Figure 2 and Supplemental figure 21**). The continuous analysis, showed that a 2-point increment in the MedDiet score was associated with a 13% lower risk of MI incidence (RR: 0.79; 95%CI: 0.67, 0.94) and there was evidence of inter-study heterogeneity (I^2 = 74%, p < 0.01) (**Supplemental figure 22**).

MI mortality

We did not identify any prospective cohort studies analyzing the association between MedDiet adherence, categorized in quantiles, and the risk of MI mortality (**Figure 2**). However, four cohort comparisons reported the risk estimate on continuous scale instead

of categories of MedDiet adherence. Pooled results showed a 13% lower risk of MI mortality (RR: 0.87; 95% CI: 0.82, 0.92) for every 2-point increment in the MedDiet score and no evidence of inter-study heterogeneity (I^2 = 0%, p = 0.51) (**Supplementary figure 23**).

Sensitivity, subgroup and dose-response analyses

In the meta-analyses of RCTs, no study modified the pooled effect estimate or the evidence of heterogeneity for any of the outcomes.

Supplemental Table 3 shows the sensitivity analyses that systematically excluded one study at a time and changed the evidence of heterogeneity or the significance, direction or magnitude of the pooled relative risk from the prospective cohort studies. Removing the study by Eguaras et al. (58) modified the heterogeneity for total CVD incidence from substantial to non-substantial. Removing the study by Warensjö et al. (70) explained the heterogeneity for CHD mortality. No study modified the pooled effect estimate or the evidence of heterogeneity for total CVD mortality, CHD incidence, stroke incidence, MI incidence, stroke mortality or MI mortality.

Supplemental figures 24 and 25 show the *a priori* and post-hoc subgroup analyses among cohort studies for CVD mortality, the only end-point with more than 10 cohort comparisons. No evidence of effect modification was observed for the association between MedDiet adherence and total CVD mortality.

Supplemental figures 26-30 show the dose-response analyses from prospective cohort studies. Five of the outcomes (total CV incidence, total CVD mortality, CHD incidence, CHD mortality and stroke incidence) had sufficient data for the dose-response analysis. No evidence of nonlinear dose-response association was detected between MedDiet adherence and these outcomes ($P_{\text{departure from linearity}} > 0.05$). A statistically significant linear association was observed between MedDiet adherence and the risk of CVD mortality,

CHD incidence, CHD mortality and stroke incidence. The RR and 95% confidence interval for every 2-point increment in the MedDiet score was 0.93 (0.92, 0.94) for CVD mortality, 0.89 (0.84, 0.94) for CHD incidence, 0.89 (0.82, 0.96) for CHD mortality and 0.92 (0.88, 0.96) for stroke incidence. For all the other outcomes we could not performed the dose-response analyses because less than 3 study comparisons were present.

Publication bias

Supplemental figure 31 shows publication bias for total CVD mortality. No evidence of publication bias was detected by visual inspection of funnel plots or by Begg ($p = 0.608$) and Egger ($p = 0.960$) tests. Due to the limited number of studies (<10 for each outcome), we could not assess publication bias for the other outcomes.

Overall quality assessment (GRADE)

Supplemental Table 3 shows the GRADE assessments for the effect of MedDiet on CVD outcomes in RCTs. The evidence for benefit was rated as moderate for total CVD incidence because of downgrade for inconsistency; low for total CVD mortality because of downgrades for inconsistency and imprecision; low for CHD incidence and CHD mortality because of downgrades for inconsistency and indirectness; moderate for stroke incidence because of downgrade for indirectness; moderate for MI incidence because of downgrade for risk of bias; and very low for MI mortality because of downgrades for risk of bias, indirectness and imprecision.

Supplemental Table 4 shows the GRADE assessments for the association between MedDiet adherence and CVD outcomes in prospective cohort studies. The evidence was rated as very low for total CVD incidence and stroke mortality because of downgrade for imprecision; very low for MI incidence because of downgrade for indirectness; low for CHD mortality because of downgrade for risk of bias and upgrade for a dose-response gradient; low for stroke incidence because of downgrade for indirectness and upgrade for

a dose-response gradient; and moderate for total CVD mortality and CHD incidence because of upgrade for a dose-response gradient.

Discussion

We conducted a meta-analysis of RCTs and prospective cohort studies to evaluate the MedDiet and the risk of incidence of or mortality from total CVD, CHD, stroke, and MI in populations inclusive of individuals with diabetes. Pooled analyses from RCTs suggest that the MedDiet reduces the risk of total CVD and MI incidence. No significant effect on total CVD mortality was reported. A meta-analysis could not be undertaken for CHD incidence and mortality, stroke incidence or MI mortality.

The results of cohort studies suggest that adherence to the MedDiet is inversely associated with the risk of incidence of or mortality from total CVD causes, except total CVD incidence and stroke mortality, when comparing the highest quantile of adherence to MedDiet to lowest quantile.

Findings in relation to other studies

Our findings from RCT meta-analyses are in line with a previous meta-analysis of RCTs that evaluated the effect of the MedDiet on various CVD outcomes (4). However, our results for total CVD mortality are inconsistent with the latest meta-analysis of RCTs, which showed a 41% lower risk of CVD death (10). This inconsistency might be explained by the fact that the authors included in the analysis two more RCTs than the present study. One of these has only sudden cardiac death as the end-point (18) and the other did not evaluate the actual definition of the MedDiet but only some of its components (73).

Our results regarding prospective cohort studies are also in line with those of previous systematic reviews and meta-analyses of observational studies evaluating the association between MedDiet and the risk of CVD outcomes (4). It is noteworthy that in the present

study, no association between MedDiet adherence and the risk of total CVD incidence was observed. However, the previous meta-analysis evaluating this association reported a 27% lower risk of CVD (7). These discrepancies could be attributable to the inclusion criteria (the present study only included studies with populations inclusive of individuals with diabetes). A further explanation may be that the meta-analysis by Grosso et al. (7) contained a mix of studies on various CVD outcomes not just a cluster of different types of CVD incidence and mortality outcomes as in the present study. In order to make the results comparable across meta-analyses, it would be important to homogenize the definition of total CVD.

The possible mechanisms by which MedDiet could prevent CVDs have been discussed in a narrative review published by our group (4). Briefly, the MedDiet is well-characterized by its high lipid (monounsaturated and polyunsaturated fatty acids), fiber, and polyphenols content, which could act synergistically modulating beneficially different CVD risk factors, such as lipid profile, blood pressure, fasting blood glucose and body weight.

Strengths and limitations

Some of the strengths of the present study need to be highlighted. First, we used a comprehensive search strategy of three main databases which identified all the RCTs and prospective cohort studies available. Second, we synthesized and quantified evidence from both RCTs and prospective cohort studies. Third, we evaluated the overall quality of the evidence by using GRADE.

Nevertheless, its limitations also need to be mentioned. Although we included both RCTs and prospective cohort studies, we cannot discount the presence of residual confounding from the observational studies, which is their main limitation. Furthermore, for the RCTs we only had one study for some analyses and no meta-analysis was performed. Another

important limitation is that the certainty of the evidence based on the GRADE approach was low or very low for most of the outcomes. Serious risk of bias were detected in the GRADE assessment for the vast majority of the outcomes from the meta-analysis of RCTs because of the inclusion of only one study (Shing et al.) (18), which appeared to have unreliable data (72), and for CHD mortality from the meta-analysis of prospective cohort studies because 50% of the studies were judged to be low quality on the NOS scale. Moreover, serious indirectness was detected for several outcomes in the meta-analysis of RCTs because only one study was included in the analyses and more than 60% of the prospective cohort studies on stroke and MI incidence had been conducted only in females. Finally, it should be pointed out that there was evidence of imprecision in the pooled estimates of total CVD and MI mortality (meta-analysis of RCTs) and in total CVD incidence and stroke mortality (meta-analyses of prospective cohorts).

Balancing the weaknesses and strengths, the overall evidence provided by the meta-analysis of RCTs was graded as very low for MI mortality; low for total CVD mortality, CHD incidence and mortality; and moderate for incidence of total CVD, stroke and MI. The overall evidence provided by the meta-analysis of prospective cohort studies was graded as very low for total CVD incidence, stroke mortality and MI incidence; low for CHD mortality and stroke incidence; and moderate for total CVD mortality and CHD incidence.

Implications

Diet is recognized as a cornerstone in the prevention of CVD in people with and without diabetes. In this regard, the role of the MedDiet in the prevention of CVD outcomes has been extensively studied in several RCTs and prospective cohort studies. Although several meta-analyses of MedDiet and CVD outcomes have been published before, the present study differs in terms of the target population. As far as we know, this is the first

meta-analysis that contains only studies with populations that includes individuals with diabetes.

Diabetes is an important predisposing risk factor for the development of CVD, the leading cause of mortality worldwide. The results of the present meta-analysis suggest a beneficial role of the MedDiet in the prevention of the incidence of and mortality from several CVD outcomes. In the light of these findings, there is clearly a need to analyze the effect of the MedDiet on CVD prevention only in individuals with diabetes, who would benefit from adopting this healthy dietary pattern.

Conclusions

In conclusion, the present systematic review and meta-analysis of prospective cohort studies and RCTs demonstrates that the MedDiet has a beneficial role in reducing the risk of the incidence of and mortality from various CVD outcomes in populations inclusive of individuals with diabetes. Our certainty in the pooled estimates ranges from moderate to very low. Future studies are likely to influence our confidence in the pooled estimates. There is an important need for new, large, well-designed RCTs conducted specifically in individuals with diabetes to address uncertainties and to develop evidence-based dietary guidelines for diabetes management.

Funding

The Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD) commissioned this systematic review and meta-analysis and provided funding and logistical support for meetings as part of their development of clinical practice guidelines for nutrition therapy. This work was supported by the Canadian Institutes of Health Research (funding reference number, 129920) through the Canada-wide Human Nutrition Trialists' Network (NTN). The Diet, Digestive tract, and Disease (3-D) Centre, funded through the Canada Foundation for Innovation (CFI) and the Ministry of Research and Innovation's Ontario Research Fund (ORF), provided the infrastructure for the conduct of this project. John L Sievenpiper was funded by a PSI Graham Farquharson Knowledge Translation Fellowship, Canadian Diabetes Association Clinician Scientist award, CIHR INMD/CNS New Investigator Partnership Prize, and Banting & Best Diabetes Centre Sun Life Financial New Investigator Award. With the exception of the Clinical Practice Guidelines Committee of the DNSG of the EASD, none of the sponsors had a role in any aspect of the present study, including design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, approval of the manuscript or decision to publish.

Conflicts of interest

Prof. Jordi Salas-Salvadó reports serving on the board of the International Nut and Dried Fruit Council, and the Eroski Foundation and receiving grant support from these entities through his institution. He also reports serving on the Executive Committee of the Instituto Danone Spain. He has received research funding from the Instituto de Salud Carlos III, Spain; Ministerio de Educación y Ciencia, Spain; Departament de Salut Pública de la Generalitat de Catalunya, Catalonia, Spain, and the European Commission. He has also received research funding from the California Walnut Commission,

Sacramento CA, USA; Patrimonio Comunal Olivarero, Spain; La Morella Nuts, Spain; and Borges S.A., Spain. He reports receiving consulting fees or travel expenses from Danone; the California Walnut Commission, the Eroski Foundation, the Instituto Danone - Spain, Nuts for Life, the Australian Nut Industry Council, Nestlé, Abbot Laboratories, and Font Vella Lanjarón. He is on the Clinical Practice Guidelines Expert Committee of the European Association for the study of Diabetes (EASD), and has served on the Scientific Committee of the Spanish Food and Safety Agency, and the Spanish Federation of the Scientific Societies of Food, Nutrition and Dietetics. He is a member of the International Carbohydrate Quality Consortium (ICQC), and Executive Board Member of the Diabetes and Nutrition Study Group (DNSG) of the EASD.

Dr. John L Sievenpiper has received research support from the Canadian Institutes of health Research (CIHR), Diabetes Canada, PSI Foundation, Banting and Best Diabetes Centre (BBDC), Canadian Nutrition Society (CNS), American Society for Nutrition (ASN), INC International Nut and Dried Fruit Council Foundation, National Dried Fruit Trade Association, The Tate and Lyle Nutritional Research Fund at the University of Toronto, The Glycemic Control and Cardiovascular Disease in Type 2 Diabetes Fund at the University of Toronto (a fund established by the Alberta Pulse Growers), and the Nutrition Trialists Fund at the University of Toronto (a fund established by the Calorie Control Council). He has received food donations to support randomized controlled trials from the Almond Board of California, California Walnut Commission, American Peanut Council, Barilla, Unilever, Unico/Primo, Loblaw Companies, Quaker (Pepsico), Kellogg Canada, and WhiteWave Foods. He has received travel support, speaker fees and/or honoraria from Diabetes Canada, Canadian Nutrition Society (CNS), Mott's LLP, Dairy Farmers of Canada, Alberta Milk, FoodMinds LLC, Memac Ogilvy & Mather LLC, PepsiCo, The Ginger Network LLC, International Sweeteners Association, Nestlé, Pulse

Canada, Canadian Society for Endocrinology and Metabolism (CSEM), GI Foundation, Abbott, Biofortis, California Walnut Commission, American Society of Nutrition (ASN), Loma Linda University, Dietitians of Canada, European Food Safety Authority, and Physicians Committee for Responsible Medicine. He has or has had ad hoc consulting arrangements with Winston & Strawn LLP, Perkins Coie LLP, Tate & Lyle, and Wirtschaftliche Vereinigung Zucker e.V. He is a member of the European Fruit Juice Association Scientific Expert Panel. He is on the Clinical Practice Guidelines Expert Committees of Diabetes Canada, European Association for the study of Diabetes (EASD), Canadian Cardiovascular Society (CCS), and Obesity Canada. He serves as an unpaid scientific advisor for the Food, Nutrition, and Safety Program (FNSP) and the Technical Committee on Carbohydrates of the International Life Science Institute (ILSI) North America. He is a member of the International Carbohydrate Quality Consortium (ICQC), Executive Board Member of the Diabetes and Nutrition Study Group (DNSG) of the EASD, and Director of the Toronto 3D Knowledge Synthesis and Clinical Trials foundation. His wife is an employee of Unilever Canada.

Dr. Cyril W.C. Kendall has received grants or research support from the Advanced Food Materials Network, Agriculture and Agri-Foods Canada (AAFC), Almond Board of California, American Pistachio Growers, Barilla, Calorie Control Council, Canadian Institutes of Health Research (CIHR), Canola Council of Canada, International Nut and Dried Fruit Council, International Tree Nut Council Research and Education Foundation, Loblaw Brands Ltd, Pulse Canada, Saskatchewan Pulse Growers and Unilever. He has received in-kind research support from the Almond Board of California, American Peanut Council, Barilla, California Walnut Commission, Kellogg Canada, Loblaw Companies, Quaker (Pepsico), Primo, Unico, Unilever, WhiteWave Foods. He has received travel support and/or honoraria from the American Peanut Council, American Pistachio

Growers, Barilla, California Walnut Commission, Canola Council of Canada, General Mills, International Nut and Dried Fruit Council, International Pasta Organization, Loblaw Brands Ltd, Nutrition Foundation of Italy, Oldways Preservation Trust, Paramount Farms, Peanut Institute, Pulse Canada, Sabra Dipping Co., Saskatchewan Pulse Growers, Sun-Maid, Tate & Lyle, Unilever and White Wave Foods. He has served on the scientific advisory board for the International Tree Nut Council, International Pasta Organization, McCormick Science Institute, Oldways Preservation Trust, Paramount Farms and Pulse Canada. He is a member of the International Carbohydrate Quality Consortium (ICQC), Executive Board Member of the Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD), is on the Clinical Practice Guidelines Expert Committee for Nutrition Therapy of the EASD and is a Director of the Toronto 3D Knowledge Synthesis and Clinical Trials foundation.

Dr. Dario Rahelić has served as principal investigator or co-investigator in clinical trials of AstraZeneca, Eli Lilly, MSD, Novo Nordisk, Sanofi Aventis, Solvay and Trophos.

He has received honoraria for speaking or advisory board engagements and consulting fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Lifescan – Johnson & Johnson, Novartis, Novo Nordisk, MSD, Merck Sharp & Dohme, Pfizer, Pliva, Roche, Salvus, Sanofi Aventis and Takeda.

No competing interests were declared by **Dr. Nerea Becerra-Tomás, Dr. Sonia Blanco Mejia, Dr. Tauseef Khan, Effie Viguiliouk and by Dr. Hana Kahleova.**

References

1. World Health Organization. WHO | Cardiovascular diseases (CVDs) [Internet]. World Health Organization; 2017 [cited 2018 Mar 27]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/
2. The Emerging Risk Factors Collaboration N, Sarwar N, Gao P, Seshasai SRK, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. World Bank and Oxford University Press, New York; 2010;375:2215–22. DOI:10.1016/S0140-6736(10)60484-9
3. Institute of Medicine (US) Committee on Preventing the, Global Epidemic of Cardiovascular Disease: Meeting the Challenges in Developing countries. Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Valentín Fuster and Bridget B Kelly, editor. Washington (DC:): National Academies Press (US); 2010. DOI:10.17226/12815
4. Salas-Salvadó J, Becerra-Tomás N, García-Gavilán JF, Bulló M, Barrubés L. Mediterranean Diet and Cardiovascular Disease Prevention: What do We Know? Prog Cardiovasc Dis. Elsevier; 2018;0. DOI:10.1016/j.pcad.2018.04.006
5. Sofi F, Macchi C, Abbate R, Gensini GF, Casini A. Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score. Public Health Nutr. 2014;17:2769–82. DOI:10.1017/S1368980013003169
6. Martinez-Gonzalez MA, Bes-Rastrollo M. Dietary patterns, Mediterranean diet, and cardiovascular disease. Curr Opin Lipidol. 2014;25:20–6. DOI:10.1097/MOL.0000000000000044
7. Grosso G, Marventano S, Yang J, Micek A, Pajak A, Scalfi L, Galvano F, Kales SN. A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: Are individual components equal? Crit Rev Food Sci Nutr. 2017;57:3218–32. DOI:10.1080/10408398.2015.1107021
8. Rosato V, Temple NJ, La Vecchia C, Castellan G, Tavani A, Guercio V. Mediterranean diet and cardiovascular disease: a systematic review and meta-analysis of observational studies. Eur J Nutr. 2017; DOI:10.1007/s00394-017-1582-0
9. Psaltopoulou T, Sergentanis TN, Panagiotakos DB, Sergentanis IN, Kosti R, Scarmeas N. Mediterranean diet, stroke, cognitive impairment, and depression: A meta-analysis. Ann Neurol. 2013;74:580–91. DOI:10.1002/ana.23944
10. Liyanage T, Ninomiya T, Wang A, Neal B, Jun M, Wong MG, Jardine M, Hillis GS, Perkovic V. Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-Analysis. Wright JM, editor. PLoS One. Public Library of Science; 2016;11:e0159252. DOI:10.1371/journal.pone.0159252
11. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. United Kingdom: The Cochrane Collaboration; 2011.
12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–12.
13. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, et al. Primary prevention of

cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279–90. DOI:10.1056/NEJMoa1200303
14. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. Massachusetts Medical Society; 2018;378:e34. DOI:10.1056/NEJMoa1800389
15. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute [Internet]. 2014 [cited 2018 Apr 11]. Available from: www.ohri.ca/programs/clinical_epidemiology/oxford.asp
16. Tsivgoulis G, Psaltopoulou T, Wadley VG, Alexandrov A V., Howard G, Unverzagt FW, Moy C, Howard VJ, Kissela B, Judd SE. Adherence to a Mediterranean Diet and Prediction of Incident Stroke. Stroke. 2015;46:780–5. DOI:10.1161/STROKEAHA.114.007894
17. Tektonidis TG, Åkesson A, Gigante B, Wolk A, Larsson SC. A Mediterranean diet and risk of myocardial infarction, heart failure and stroke: A population-based cohort study. Atherosclerosis. 2015;243:93–8. DOI:10.1016/j.atherosclerosis.2015.08.039
18. Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D, Berry EM. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet. 2002;360:1455–61. DOI:10.1016/S0140-6736(02)11472-3
19. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280:1690–1.
20. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol. 2002;55:893–9.
21. Chrysohoou C, Panagiotakos DB, Aggelopoulos P, Kastorini C-M, Kehagia I, Pitsavos C, Stefanadis C. The Mediterranean diet contributes to the preservation of left ventricular systolic function and to the long-term favorable prognosis of patients who have had an acute coronary event. Am J Clin Nutr. 2010;92:47–54. DOI:10.3945/ajcn.2009.28982
22. Kouvari M, Chrysohoou C, Aggelopoulos P, Tsiamis E, Tsioufis K, Pitsavos C, Tousoulis D. Mediterranean diet and prognosis of first-diagnosed Acute Coronary Syndrome patients according to heart failure phenotype: Hellenic Heart Failure Study. Eur J Clin Nutr. 2017;71:1321–8. DOI:10.1038/ejcn.2017.122
23. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99:779–85.
24. Aigner A, Becher H, Jacobs S, Wilkens LR, Boushey CJ, Le Marchand L, Haiman CA, Maskarinec G. Low diet quality and the risk of stroke mortality: the multiethnic cohort study. Eur J Clin Nutr. 2018; DOI:10.1038/s41430-018-0103-4
25. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean Diet and Survival in a Greek Population. N Engl J Med [Internet]. 2003 [cited 2017 Jun 14];348:2599–608. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12826634DOI:10.1056/NEJMoa025039

26. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose–response data. Stata J. 2006;6:40–57.
27. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol. 1992;135:1301–9.
28. Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2012;175:66–73. DOI:10.1093/aje/kwr265
29. Bekkering GE, Harris RJ, Thomas S, Mayer A-MB, Beynon R, Ness AR, Harbord RM, Bain C, Smith GD, Sterne JAC. How Much of the Data Published in Observational Studies of the Association between Diet and Prostate or Bladder Cancer Is Usable for Meta-Analysis? Am J Epidemiol. 2008;167:1017–26. DOI:10.1093/aje/kwn005
30. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
31. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. Elsevier; 2011;64:383–94. DOI:10.1016/j.jclinepi.2010.04.026
32. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol. Elsevier; 2011;64:407–15. DOI:10.1016/j.jclinepi.2010.07.017
33. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. British Medical Journal Publishing Group; 2011;343:d5928. DOI:10.1136/BMJ.D5928
34. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Glasziou P, Jaeschke R, Akl EA, et al. GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol. 2011;64:1294–302. DOI:10.1016/j.jclinepi.2011.03.017
35. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, Alonso-Coello P, Falck-Ytter Y, Jaeschke R, Vist G, et al. GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol. 2011;64:1303–10. DOI:10.1016/j.jclinepi.2011.04.014
36. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux PJ, Montori VM, Freyschuss B, Vist G, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. Elsevier; 2011;64:1283–93. DOI:10.1016/j.jclinepi.2011.01.012
37. Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, Alonso-Coello P, Djulbegovic B, Atkins D, Falck-Ytter Y, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol. Elsevier; 2011;64:1277–82. DOI:10.1016/j.jclinepi.2011.01.011
38. Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, Atkins D, Kunz R, Brozek J, Montori V, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64:1311–6. DOI:10.1016/j.jclinepi.2011.06.004
39. Buckland G, González CA, Agudo A, Vilardell M, Berenguer A, Amiano P, Ardanaz E, Arriola L, Barricarte A, Basterretxea M, et al. Adherence to the

Mediterranean diet and risk of coronary heart disease in the Spanish EPIC Cohort Study. Am J Epidemiol. 2009;170:1518–29. DOI:10.1093/aje/kwp282
40. Buckland G, Agudo A, Travier N, Huerta JM, Cirera L, Tormo M-J, Navarro C, Chirlaque MD, Moreno-Iribas C, Ardanaz E, et al. Adherence to the Mediterranean diet reduces mortality in the Spanish cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC-Spain). Br J Nutr. 2011;106:1581–91. DOI:10.1017/S0007114511002078
41. Chiuve SE, Fung TT, Rexrode KM, Spiegelman D, Manson JE, Stampfer MJ, Albert CM. Adherence to a low-risk, healthy lifestyle and risk of sudden cardiac death among women. JAMA. 2011;306:62–9. DOI:10.1001/jama.2011.907
42. Gardener H, Wright CB, Gu Y, Demmer RT, Boden-Albala B, Elkind MS V, Sacco RL, Scarmeas N. Mediterranean-style diet and risk of ischemic stroke, myocardial infarction, and vascular death: the Northern Manhattan Study. Am J Clin Nutr. 2011;94:1458–64. DOI:10.3945/ajcn.111.012799
43. Martínez-González MA, García-López M, Bes-Rastrollo M, Toledo E, Martínez-Lapiscina EH, Delgado-Rodriguez M, Vazquez Z, Benito S, Beunza JJ. Mediterranean diet and the incidence of cardiovascular disease: A Spanish cohort. Nutr Metab Cardiovasc Dis. 2010;21:237–44. DOI:10.1016/j.numecd.2009.10.005
44. Dilis V, Katsoulis M, Lagiou P, Trichopoulos D, Naska A, Trichopoulou A. Mediterranean diet and CHD: the Greek European Prospective Investigation into Cancer and Nutrition cohort. Br J Nutr. 2012;108:699–709. DOI:10.1017/S0007114512001821
45. Misirli G, Benetou V, Lagiou P, Bamia C, Trichopoulos D, Trichopoulou A. Relation of the Traditional Mediterranean Diet to Cerebrovascular Disease in a Mediterranean Population. Am J Epidemiol. 2012;176:1185–92. DOI:10.1093/aje/kws205
46. Tognon G, Nilsson LM, Lissner L, Johansson I, Hallmans G, Lindahl B, Winkvist A. The Mediterranean diet score and mortality are inversely associated in adults living in the subarctic region. J Nutr. 2012;142:1547–53. DOI:10.3945/jn.112.160499
47. Atkins JL, Whincup PH, Morris RW, Lennon LT, Papacosta O, Wannamethee SG. High Diet Quality Is Associated with a Lower Risk of Cardiovascular Disease and All-Cause Mortality in Older Men. J Nutr. 2014;144:673–80. DOI:10.3945/jn.113.186486
48. Bertoia ML, Triche EW, Michaud DS, Baylin A, Hogan JW, Neuhouser ML, Tinker LF, Van Horn L, Waring ME, Li W, et al. Mediterranean and Dietary Approaches to Stop Hypertension dietary patterns and risk of sudden cardiac death in postmenopausal women. Am J Clin Nutr. 2014;99:344–51. DOI:10.3945/ajcn.112.056135
49. Booth JN, Levitan EB, Brown TM, Farkouh ME, Safford MM, Muntner P. Effect of Sustaining Lifestyle Modifications (Nonsmoking, Weight Reduction, Physical Activity, and Mediterranean Diet) After Healing of Myocardial Infarction, Percutaneous Intervention, or Coronary Bypass (from the REasons for Geographic and Racial Differences in Stroke Study). Am J Cardiol. 2014;113:1933–40. DOI:10.1016/j.amjcard.2014.03.033
50. Cuenca-García M, Artero EG, Sui X, Lee D, Hebert JR, Blair SN. Dietary indices, cardiovascular risk factors and mortality in middle-aged adults: findings from the Aerobics Center Longitudinal Study. Ann Epidemiol. 2014;24:297–303.e2. DOI:10.1016/j.annepidem.2014.01.007

51. George SM, Ballard-Barbash R, Manson JE, Reedy J, Shikany JM, Subar AF, Tinker LF, Vitolins M, Neuhouser ML. Comparing indices of diet quality with chronic disease mortality risk in postmenopausal women in the Women's Health Initiative Observational Study: evidence to inform national dietary guidance. Am J Epidemiol. 2014;180:616–25. DOI:10.1093/aje/kwu173
52. Lopez-Garcia E, Rodriguez-Artalejo F, Li TY, Fung TT, Li S, Willett WC, Rimm EB, Hu FB. The Mediterranean-style dietary pattern and mortality among men and women with cardiovascular disease. Am J Clin Nutr. 2014;99:172–80. DOI:10.3945/ajcn.113.068106
53. Reedy J, Krebs-Smith SM, Miller PE, Liese AD, Kahle LL, Park Y, Subar AF. Higher diet quality is associated with decreased risk of all-cause, cardiovascular disease, and cancer mortality among older adults. J Nutr. 2014;144:881–9. DOI:10.3945/jn.113.189407
54. Schröder H, Salas-Salvadó J, Martínez-González MA, Fíto M, Corella D, Estruch R, Ros E. Baseline Adherence to the Mediterranean Diet and Major Cardiovascular Events: Prevención con Dieta Mediterránea Trial. JAMA Intern Med. 2014;174:1690. DOI:10.1001/jamainternmed.2014.3463
55. Tognon G, Lissner L, Sæbye D, Walker KZ, Heitmann BL. The Mediterranean diet in relation to mortality and CVD: a Danish cohort study. Br J Nutr. 2014;111:151–9. DOI:10.1017/S0007114513001931
56. Vormund K, Braun J, Rohrmann S, Bopp M, Ballmer P, Faeh D. Mediterranean diet and mortality in Switzerland: an alpine paradox? Eur J Nutr. 2015;54:139–48. DOI:10.1007/s00394-014-0695-y
57. Bonaccio M, Di Castelnuovo A, Costanzo S, Persichillo M, De Curtis A, Donati MB, de Gaetano G, Iacoviello L, MOLI-SANI study Investigators. Adherence to the traditional Mediterranean diet and mortality in subjects with diabetes. Prospective results from the MOLI-SANI study. Eur J Prev Cardiol. 2016;23:400–7. DOI:10.1177/2047487315569409
58. Eguaras S, Toledo E, Hernández-Hernández A, Cervantes S, Martínez-González MA. Better Adherence to the Mediterranean Diet Could Mitigate the Adverse Consequences of Obesity on Cardiovascular Disease: The SUN Prospective Cohort. Nutrients. 2015;7:9154–62. DOI:10.3390/nu7115457
59. Lau K-K, Wong Y-K, Chan Y-H, Li O-Y, Lee PY-S, Yuen GG, Wong Y-K, Tong S, Wong D, Chan K-H, et al. Mediterranean-style diet is associated with reduced blood pressure variability and subsequent stroke risk in patients with coronary artery disease. Am J Hypertens. 2015;28:501–7. DOI:10.1093/ajh/hpu195
60. Panagiotakos DB, Georgousopoulou EN, Pitsavos C, Chrysohoou C, Skoumas I, Pitaraki E, Georgiopoulos GA, Ntertimani M, Christou A, Stefanadis C, et al. Exploring the path of Mediterranean diet on 10-year incidence of cardiovascular disease: the ATTICA study (2002-2012). Nutr Metab Cardiovasc Dis. 2015;25:327–35. DOI:10.1016/j.numecd.2014.09.006
61. Pignatelli P, Pastori D, Farcomeni A, Nocella C, Bartimoccia S, Vicario T, Bucci T, Carnevale R, Violi F. Mediterranean diet reduces thromboxane A2 production in atrial fibrillation patients. Clin Nutr. 2015;34:899–903. DOI:10.1016/j.clnu.2014.09.011
62. Bo S, Ponzo V, Goitre I, Fadda M, Pezzana A, Beccuti G, Gambino R, Cassader M, Soldati L, Broglio F. Predictive role of the Mediterranean diet on mortality in individuals at low cardiovascular risk: a 12-year follow-up population-based cohort study. J Transl Med. 2016;14:91. DOI:10.1186/s12967-016-0851-7

63. Park Y-M, Steck SE, Fung TT, Zhang J, Hazlett LJ, Han K, Merchant AT. Mediterranean diet and mortality risk in metabolically healthy obese and metabolically unhealthy obese phenotypes. Int J Obes (Lond). 2016;40:1541–9. DOI:10.1038/ijo.2016.114
64. Shvetsov YB, Harmon BE, Ettienne R, Wilkens LR, Le Marchand L, Kolonel LN, Boushey CJ. The influence of energy standardisation on the alternate Mediterranean diet score and its association with mortality in the Multiethnic Cohort. Br J Nutr. 2016;116:1592–601. DOI:10.1017/S0007114516003482
65. Stewart RAH, Wallentin L, Benatar J, Danchin N, Hagström E, Held C, Husted S, Lonn E, Stebbins A, Chiswell K, et al. Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. Eur Heart J. 2016;37:1993–2001. DOI:10.1093/eurheartj/ehw125
66. Tong TYN, Wareham NJ, Khaw K-T, Imamura F, Forouhi NG. Prospective association of the Mediterranean diet with cardiovascular disease incidence and mortality and its population impact in a non-Mediterranean population: the EPIC-Norfolk study. BMC Med. 2016;14:135. DOI:10.1186/s12916-016-0677-4
67. Hodge AM, Bassett JK, Dugué P-A, Shivappa N, Hébert JR, Milne RL, English DR, Giles GG. Dietary inflammatory index or Mediterranean diet score as risk factors for total and cardiovascular mortality. Nutr Metab Cardiovasc Dis. 2018;28:461–9. DOI:10.1016/j.numecd.2018.01.010
68. Shah NS, Leonard D, Finley CE, Rodriguez F, Sarraju A, Barlow CE, DeFina LF, Willis BL, Haskell WL, Maron DJ. Dietary Patterns and Long-Term Survival: A Retrospective Study of Healthy Primary Care Patients. Am J Med. 2018;131:48–55. DOI:10.1016/j.amjmed.2017.08.010
69. Whalen KA, Judd S, McCullough ML, Flanders WD, Hartman TJ, Bostick RM. Paleolithic and Mediterranean Diet Pattern Scores Are Inversely Associated with All-Cause and Cause-Specific Mortality in Adults. J Nutr. 2017;147:612–20. DOI:10.3945/jn.116.241919
70. Warensjö Lemming E, Byberg L, Wolk A, Michaëlsson K. A comparison between two healthy diet scores, the modified Mediterranean diet score and the Healthy Nordic Food Index, in relation to all-cause and cause-specific mortality. Br J Nutr. 2018;119:836–46. DOI:10.1017/S0007114518000387
71. Al Rifai M, Greenland P, Blaha MJ, Michos ED, Nasir K, Miedema MD, Yeboah J, Sandfort V, Frazier-Wood AC, Shea S, et al. Factors of health in the protection against death and cardiovascular disease among adults with subclinical atherosclerosis. Am Heart J. 2018;198:180–8. DOI:10.1016/j.ahj.2017.10.026
72. Horton R. Expression of concern: Indo-Mediterranean Diet Heart Study. Lancet (London, England). Elsevier; 2005;366:354–6. DOI:10.1016/S0140-6736(05)67006-7
73. Burr ML, Ashfield-Watt PAL, Dunstan FDJ, Fehily AM, Breay P, Ashton T, Zotos PC, Haboubi NAA, Elwood PC. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr. Nature Publishing Group; 2003;57:193–200. DOI:10.1038/sj.ejcn.1601539
74. Panagiotakos DB, Georgousopoulou EN, Pitsavos C, Chrysohoou C, Skoumas I, Pitaraki E, Georgiopoulos GA, Ntertimani M, Christou A, Stefanadis C, et al. Exploring the path of Mediterranean diet on 10-year incidence of cardiovascular disease: the ATTICA study (2002-2012). Nutr Metab Cardiovasc Dis. 2015;25:327–35. DOI:10.1016/j.numecd.2014.09.006

Figure 1 PRISMA flow diagram

Figure 2. Summary of the pooled-effect estimates of randomized clinical trials and prospective cohort studies assessing the effect/association between Mediterranean diet and cardiovascular disease outcomes. Analyses were conducted using generic inverse variance random-effects models (≥ 5 trials available) or fixed effects models (<5 trials available). The pooled risk estimates are presented by the circle. $I^2 \geq 50\%$ indicates substantial heterogeneity. CI= confidence interval; CVD = cardiovascular disease; CHD=coronary heart disease.

Table 1. Characteristics of randomized clinical trials evaluating the effect of Mediterranean diet adherence and cardiovascular disease and mortality outcomes

Study	Design	Participants	Mean age (SD or range), y	Treatment group	Control group	Follow-up	Outcome	Country	Funding sources
De Lorgeril et al., 1999 (23) Control group Experimental group	Randomized single-blind, multi-clinic secondary prevention trial	605 303 302	53.5 (10)	Mediterranean diet	Close to step I diet of the American Heart Association	27 months	Total CVD incidence Total CVD mortality	France	NR
Singh et al., 2002 (18) Control group Experimental group	Randomized single-blind, parallel, clinical trial	1000 501 499	48 (9) 49 (10)	Indo-Mediterranean diet	Prudent diet (NCE) in step I	2 years	MI incidence MI mortality CHD incidence CHD mortality	India	Agency
Estruch et al., 2018 (14) Control group Experimental group Experimental group	Randomized parallel, multicenter clinical trial	7447 2543 2454 2450	Men 50-80 Women 60-80	MedDiet + EVOO MedDiet + nuts	Low-fat diet	4.8 years	Total CVD incidence Total CVD death Stroke MI incidence	Spain	Agency-Industry

CHD, coronary heart disease; CVD, cardiovascular disease; EVOO, extra virgin olive oil; MedDiet, Mediterranean Diet; MI, myocardial infarction; NR, non-reported

Table 2. Characteristics of prospective cohort studies evaluating the association between Mediterranean diet adherence and cardiovascular disease and mortality.

Author, year	Country	Study name	Participants	Age	Follow-up	Type of score	Divisions	Outcome	Total incidence	Adjustments	Founding source	NOS
Buckland et al, 2009 (39)	Spain	EPIC-Heart	40,757 (15,335M/25,422 F)	29-69	mean of 10.4y	Variation of Trichopolou method: relative MedDiet (score rangin 0-18)	3 categories: Low adherence, medium adherence and high adherence As continuous:2-point increase	CHD incidence	609	Stratified by age, sex, center. Adjusted for education, physical activity, BMI, smoking status, diabetes, hypertension and hyperlipidemia status and total calorie intake	Agency	9
Chrysohoou et al, 2010(21)	Greece	-	750	63 (13) males 69 (12) females	2y	Panagiotakos MedDiet score ranging from 0 to 55	3 categories: Low: <16 Moderate: 17-20 High: >21	Total CVD incidence	464	Age, sex, physical activity, smoking, BMI, hypertension, hypercholesterolemia, diabetes, history of CVD, family history of CVD, revascularization, ejection fraction, creatinine clearance at entry, c-reactive protein and discharge diagnosis	-	5
Buckland et al, 2011(40)	Spain	EPIC-Spain	40,622 (15,324M/25,298 F)	29-69	mean of 13,4y	Trichopolou method adaptation (score ranging 0-18)	3 categories: Low adherence, medium adherence and high adherence	Total CVD mortality	399	Stratified by center, age and sex. Adjusted for BMI, waist circumference, education level, physical activity, smoking status	Agency	8

							As continuous:2-point increase			and intensity and total energy intake.		
Chiuve et al, 2011(41)	United States	NHS	81,722F	30-55	26y	Alternate MedDiet score (ranging 0-9)	Five categories (cumulative score): <2.5 2.5-3.4 3.5-4.2 4.3-5.4 >5.4	CHD mortality	321	age (months), family history of myocardial infarction (no history, family member 60 years, family member 60 years), menopausal status (yes or no), current hormone therapy use (yes or no), and presence of diabetes, hypertension, high cholesterol, cancer, coronary heart disease, or stroke at baseline (all yes or no).	Agency	6
Gardener et al, 2011(42)	United States	NOMAS	2,568 (931M/1,637F)	68.6 (10.3)	mean of 9 y	Trichopolou method (ranging 0-9)	Quintiles As continuous:1-point increase	Total CVD incidence Ischemic stroke MI incidence Total CVD mortality	518 171 133 314	Age, sex, race-ethnicity, completion of high school education, moderate-to-heavy physical activity, kilocalories, cigarette smoking, hypertension, diabetes, hypercholesterolemia and history of	Agency	8

										self-reported cardiac disease		
Martinez-Gonzalez et al, 2011(43)	Spain	SUN	13,609 (5,444M/8,165F)	38	Median of 4.9y	Trichopolou method (ranging 0-9)	4 categories: Low Low-moderate: Moderate-high High As continuous per each 2-point increase	Total CVD incidence CHD incidence	100 68	Age, sex, family history of coronary heart disease, total energy intake, physical activity, smoking, BMI, diabetes at baseline, use of aspirin, history of hypertension and history of hypercholesterolemia.	Agency	8
Dilis et al, 2012(44)	Greece	Greek EPIC-cohort	23,929 (9,740M/14,189F)	20-86	median of 10y	Trichopolou method (ranging 0-9)	3 categories: 0-3 4-5 6-9 As continuous:2-point increase	CHD incidence CHD mortality	636 240	Age, sex, BMI, height, physical activity, years of schooling, energy intake, smoking status, arterial blood pressure.	Agency	8
Misirli et al, 2012(45)	Greece	EPIC-Greece	23,601 (9,617M/13,984F)	20-86	Median of 10.6 years	Trichopolou method (ranging from 0-9)	3 categories: 0-3 4-5 6-9 As continuous:2-point increase	Stroke incidence Stroke mortality Ischemic stroke incidence Hemorrhagic stroke incidence	395 196 95 59	sex, age, education, smoking status, body mass index, level of physical activity, hypertension, diabetes and total energy intake	Agency	8
Tognon et al, 2012(46)	Sweden	The Västerbotten	73984 (35950M/38034F)	30-60	Median of 9 years	Trichopolou method	As continuous:1-point increase	Total CVD mortality	680	Age, obesity, smoking status,	Agency-Industry	6

		Intervention Programme				(ranging from 0-8)		MI mortality Stroke mortality	305 144	education, and physical activity		
Atkins et al, 2014(47)	Great Britain	British Regional Heart Study	3,163M	60-79	mean of 11.3y	Trichopolou method (Ranging 0-8)	Quartiles	Total CVD mortality Total CVD incidence CHD incidence	302 545 288	Age, energy intake, smoking status, alcohol intake, physical activity, social class, BMI, HDL cholesterol, SBP, diabetes, CRP and vWF	Agency	7
Bertoia et al, 2014(48)	United States	WHI	93,122F	50-79	mean of 10.5y	Trichopolou method (Ranging 0-40)	Quintiles of updated score (baseline and 3 years)	CHD mortality	237	CAD, congestive heart failure, diabetes, hypertension, age, total energy, race, income, smoking, physical activity, waist to hip ratio, BMI, pulse.	Agency	6
Booth et al, 2014(49)	United States	REGARDS-study	4,174 (2,675M/1,499F)	≥45	median of 4.3y	Method similar to Trichopolou with 14 components	Quartiles	CHD incidence	447	age, race, sex, and region of residence, education and income, LDL cholesterol, systolic and diastolic blood pressure, self-rated health, diabetes, albuminuria, estimated glomerular filtration rate, C-reactive protein, aspirin use,	Agency	6

										clopidogrel use, beta blocker use, angiotensin converting enzyme inhibitor use, angiotensin receptor blocker use, and statin use		
Cuenca-Garcia et al, 2014(50)	Dallas, Texas	ACLS	12,193 (9,353M/2,840F)	20-82	mean of 11.6y	Based on Trichopolou method (ranging 0-9)	Quartiles	Total CVD mortality	102	age, sex, energy intake, examination year, physical activity, smoking, abnormal electrocardiogram, parental history of premature CVD and cardiorespiratory fitness	Agency-Industry	7
George et al, 2014(51)	United States	WHI Extension study	63,805F	50-79	median of 12.9y	Alternate Mediterranean Diet (ranging 0-9)	Quintiles	Total CVD mortality	1483	Age, energy intake, ethnicity, educational level, marital status, smoking, physical activity, postmenopausal hormone replacement therapy, body mass index and diabetes status	Agency	6
Lopez-Garcia et al, 2014(52)	United States	HPFS	6,137M	40-75	median of 7.7y	Alternate Mediterranean Diet score (ranging 0-9)	Quintiles of cumulative MedDiet score As continuous per each 2-point increase	Total CVD mortality	1142	age , smoking status, BMI , leisure-time physical activity, parental history of myocardial infarction before age 65 y,	Agency	7

		NHS	11,278F	30-55	median of 5.8y				666	multivitamin use, menopausal status and use of HT in women and medication use (aspirin, diuretics, b-blockers, calcium channel blockers, other blood pressure medication, or statins and other cholesterol-lowering drugs)		
Reedy et al, 2014(53)	United States	NIH-AARP Diet and Health Study	424,663 (242,321 M/182,342F)	50-71	15y	Alternate Mediterranean diet score 0-9	Quintiles	Total CVD mortality	23,502	age, race/ethnicity, education, marital status, physical activity, smoking, energy intake, BMI and diabetes	-	7
Schroder et al, 2014(54)	Spain	PREDIMED study	7,447 (3,165M/4,282F)	Males 55-80 Females 60-80	Median of 4.8y	MedDiet adherence questionnaire	As continuous per each 2-point increase	Total CVD incidence Total CVD mortality Stroke incidence MI incidence	288 87 139 106	age, gender, smoking, diabetes mellitus, hypertension, dyslipidemia, body mass index, family history of premature coronary heart disease, recruiting center, intervention group, leisure-time physical activity and educational level	Agency-Industry	9
Tognon et al, 2014(55)	Denmark	Danish MONICA project	1,849 (901M/948F)	25–74	Average of	Modified MedDiet score 0-8:	As continuous per each 1-point increase	Total CVD incidence	755 223	sex, BMI, education, physical activity		7

					14years	adapted from Trichopolou		Total CVD mortality MI incidence MI mortality Stroke incidence Stroke mortality	161 64 167 40	and cigarette smoking, blood pressure, TAG and total cholesterol:HDL-cholesterol ratio		
Vormund et al, 2014(56)	Switzerland	The National Research Program 1A (NRP 1A) The Swiss MONICA study	17,861 (8,665M/ 9,196F)	16–92 25-74		Modified MedDiet score 0-9: adapted from Trichopolou	3 categories	Total CVD mortality	1,385	age, sex and survey wave; marital status, smoking, BMI, region and nationality	Agency	7
Bonaccio, et al 2015(57)	Italy	MOLI-SANI study	1,995 (1,319M/676F)	62.6 (10.2)	median of 4y	Trichopolou method (Ranging 0-9)	3 categories: Poor, average and high As continuous:2-point increase	Total CVD mortality	51	Age, sex, smoking, physical activity, energy, education, years of diabetes diagnosis, blood glucose levels, hypercholesterolemia.	Agency-industry	7
Eguaras et al, 2015(58)	Spain	SUN	19,065 (7,531M/11,534F)	21-85	mean of 10.9y	Trichopolou method (ranging 0-9)	4 categories: Low, low-to-moderate, Moderate-to-High and High As continuous:2-point increase	Total CVD incidence	152	Age (underline time variable plus stratification), sex, smoking, baseline hypercholesterolemia, hypertension, leisure-time physical activity, diabetes and previous history of cardiovascular disease.	Agency	6

Lau et al, 2015(59)	Hong Kong	-	274 (212M/62F)	68 (10)	mean of 77 (12) months	Trichopolou 0-8	As continuous per each 1 point increase	Stroke incidence	13	Age, sex, BMI, smoking, diabetes, hypercholesterolemia, mean systolic BP, family history of CVD, CVD medication and hypertension	Agency	6
Panagiotakos et al, 2015 (74)	Greece	ATTICA study	2,009	18-89	Median of 8.4	Panagiotakos method (ranging 0-55)	As continuous per each 1 point increase	Total CVD incidence	299	age, sex, smoking, physical activity, diabetes, hypercholesterolemia, hypertension, waist-hip ratio, years of school, family history of cvd, CRP and IL-6	Industry	8
Pignatelli et al, 2014(61)	Italy	-	801	73.6 (8.9)	Mean of 39.9 months	Mediterranean diet questionnaire ranging 0-9	3 categories: Low: 0–3 intermediate: 4–6 High: 7–9	Total CVD incidence	72	sNOX2-dp, F2-IsoP, arterial hypertension, diabetes, HF, prior stroke/TIA, prior MI/CHD, age, gender, antiplatelets, ACE inhibitors/ARBs, b-blockers, and statins	-	5
Tektonidis, et al 2015(17)	Sweden	SMC	32,921F	48-83	Mean of 10.4y	Modified MedDiet score (Ranging 0-8) adapted from Trichopolou	Quartiles As continuous per each 1-point increase	MI incidence Ischemic stroke Hemorrhagic stroke	1109 1270 262	education level , family history of myocardial infarction, cigarette smoking , physical acitivity, BMI, history of	Agency	8

										hypertension, history of hypercholesterolemia, history 12 of diabetes, aspirin use and total energy intake		
Tsivgoulis et al, 2015(16)	United States	REGARDS-study	20,197 (8,853M/11,344F)	≥45	Mean of 6.5 years	Trichopolou method (Ranging 0-9)	3 categories	Stroke incidence Ischemic stroke Hemorrhagic stroke	565 497 68	age, race, age-race interaction, region, sex, income, education, total energy, smoking status, sedentary behavior, history of heart disease, atrial fibrillation, body mass index, waist circumference, diabetes mellitus, hypertension, hypertension medication use, systolic and diastolic blood pressure levels	Agency	7
Bo et al, 2016(62)	Italy	-	1,658	45-64	mean of 12y	Trichopolou method (Ranging 0-9)	3 categories: Low, medium and high. As continuous per 1-unit increase	Total CVD incidence Total CVD mortality	125 84	Age, sex, BMI, smoking, Physical activity, Total cholesterol, HDL-c, SBP, DBP, fasting glucose, education, rural area, CVD score	Agency	7
Park et al, 2016(63)	United States	NHANES	598 MHO	20–88	Median of 18.5 years	Panagiotakos method (ranging 0-50)	Tertiles	Total CVD mortality	16	age, gender, race/ethnicity, educational attainment, income, living	-	8

			1141 MUO				As continuous per each 5-point increase		86	with spouse, smoking status, level of physical activity, family history of coronary heart disease, body mass index and total calorie intakes.		
Shvetsov et al, 2016(64)	United States	MEC	193,527 (87,338 M/106,189F)	45-75	13-18y	Alternate Mediterranean diet score 0-9	Quintiles	Total CVD mortality	10433 males 8567 females	age, ethnicity, BMI, physical activity, smoking, education, marital status, hormone replacement therapy (women only) and history of diabetes, heart disease and cancer	Agency	7
Stewart et al, 2016(65)	International	STABILITY	15,482	67 (9)	Median of 3,7 years	Method described by Sofi et al.	As continuous per each 1-point increase	Total CVD incidence Total CVD mortality MI incidence Stroke incidence	1588 623 698 267	treatment group, age, sex, smoking, markers of disease severity, history of hypertension, diabetes mellitus, HDL and LDL cholesterol, body mass index, and total physical activity, geographic region, World Bank Country income level, education and Western Dietary Score	Industry	6

Tong et al, 2016(66)	United Kingdom	EPI- Norfolk cohort	23,902	40-79	Average of 12.2 years	Trichopolou 0-9	3 categories (cumulative score): Low, medium and high As continuous per SD difference	Total CVD incidence Total CVD mortality CHD incidence CHD mortality Stroke incidence Stroke mortality	7606 1714 2967 817 1023 509	Age, sex, BMI, smoking, physical activity, diabetes, education, social class, marital status, season of FFQ assessment, waist circumference, medication use, family history of diabetes, MI and stroke	Agency	8
Kouvari et al, 2017(22)	Greece	Hellenic Heart Failure Study	690 (483M/207F)	62 (12)	10 years	Panagiotakos ranging 0-55	continuous per each 1-point increment	CHD incidence	345	Age, gender, BMI, physical activity, hypertension, hypercholesterolemia, diabetes mellitus, family history of CVD, left ventricular ejection fraction	-	7
Whalen et al, 2017(69)	USA	REGARDS-study	21423	≥45	median of 6.25 years	Modified MedDiet score (ranging 11-55)	Quintiles	Total CVD mortality	863	sex, race, total energy intake, BMI, physical activity, smoking, annual income, hormone replacement therapy use (in women) at baseline in an age (in months)-as-time-scale model	Agency	7
Hodge et al, 2018(67)	Australia	MCCS	39,532 (16051M/23481F)	40-69	Average of 9 years	Trichopolou method (ranging 0-9)	Tertiles As continuous: 1-point increment	Total CVD mortality CHD mortality	2081 140	birth, SEIFA quintile, alcohol intake, personal history of diabetes, stratified	Agency	7

										by sex and personal and family history of CVD; CVD model includes DII x attained age interaction.		
Shah et al, 2018(68)	USA	The Cooper Center Longitudinal Study	11376 (8577M/2799F)	≥ 20	mean of 18 years	Trichopoulou method (Rangin 0-9)	Quintiles	Total CVD mortality	249	Adjusted for sex, age, smoking, calorie intake, physical activity, BMI, family history cardiovascular disease, and baseline glucose, LDL, and SBP	-	8
Warensjö et al, 2018(70)	Sweden	SMC	30338F 32260F	49−83	median of 17y	Trichopoulou method (Rangin 0-8)	Tertiles	Total CVD mortality CHD mortality	3003 1081	Educational level, living alone, physical activity, energy intake, smoking habits, Charlson's comorbidity index and healthy diet score	Agency	6
Rifai et al, 2018(71)	USA	MESA	1601	45-84	Median of 12.1 years	Trichopolou method (ranging 0-11)	Quartiles	Total CVD incidence	276	Age, sex, race/ethnicity, education, MESA site, income, occupational status, marital status, family history of CHD, presence of diabetes, presence of hypertension, baseline statin use, baseline aspirin use,	-	6

										baseline anti-hypertensive medication use, baseline glucose-lowering medication use		
Aigner et al, 2018(24)	USA	MEC	172043 (80380M/91663F)	45-75	17.6 years	Trichopoulou method (Rangin 0-9)	Three categories: High Medium Low	Stroke mortality	3548	sex, ethnicity, age, BMI, physical activity, hormone therapy, education, USA born, >25 years in USA	Agency	7

ACLS (Aerobics Center Longitudinal Study); CHD, coronary heart disease; COSM (Cohort of Swedish Men); CVD, Cardiovascular disease; HPFS (Health professionals follow-up study); MEC (Multiethnic cohort Study; NOMAS (Northern Manhattan Study); MESA (Multi-Ethnic Study of Atherosclerosis); MI, myocardial infarction; NHS (Nurses' Health Study); REGARDS-study (REasons for Geographic and Racial Differences in Stroke); SMC (Swedish Mammography Cohort); SUN (Seguimiento Universidad de Navarra); WHI Extension study (Women's Health Initiative)


Identification
Screening
Eligibility
Included
Records identified through database searching (n = 2592)
Additional records identified through manual search (n = 1)
Records after duplicates removed (n = 1448)
Records screened (n = 1448)
Records excluded based on title/abstract (n = 1323)
No prospective cohort studies or RCTs; n = 120
No assessment of MedDiet as exposure; n = 276
Letter/comments/viewpoints/summaries for patients/editorials and opinion articles; n = 67
Abstracts/proceedings/symposiums/presentations and invited lecturers; n = 340
Reviews/meta-analyses; n = 192
Guidelines or scientific statements; n = 6
Animal studies; n = 3
Studies with irrelevant outcomes; n = 318
Impossibility to compare with other studies; n=1
Full-text articles assessed for eligibility (n = 125)
Full-text articles excluded, with reasons (n = 84)
Duplicates; n = 1
No prospective cohort studies or RCTs; n = 3
No assessment of MedDiet as exposure; n = 2
Abstracts/proceedings/symposiums/presentations and invited lecturers; n = 2
Reviews/meta-analyses; n = 16
No relevant outcome; n = 13
Duplicate prospective cohort study/RCT with shorter follow-up; n = 18
A-posteriory MedDiet adherence assessment; n = 8
No RRs, HRs or ORs reported; n = 1
Impossibility to compare with other studies; n = 2
Data irretrievable; n = 1
No inclusion of individuals with diabetes; n = 17
Studies included in quantitative synthesis (meta-analysis) (n = 41)
Total CVD incidence: n= 8 reports
Total CVD mortality: n= 16 reports (21 study comparisons)
CHD incidence: n= 5 reports (7 study comparisons)
CHD mortality: n= 5 reports (6 study comparisons)
Stroke incidence: n= 4 reports (5 study comparisons)
Stroke mortality: n= 2 reports (4 study comparisons)
MI incidence: n= 2 reports
MI mortality n= 0 studies

Figure 1. PRISMA flow diagram. CHD, coronary heart disease; CVD, cardiovascular disease; MedDiet, Mediterranean Diet; MI, myocardial infarction; RCTs, randomized clinical trials;


GRADE
Subgroup
No.
N
RR [95% CI]
Pooled RR [95% CI]
Heterogeneity
I²%
P-Value
P-value
Risk of bias
Inconsistency
Indirectness
Imprecision
Publication bias
Dose-response
Certainty
Randomized Clinical Trials
Total CVD incidence 2 8,052 0.62 [0.50, 0.78] 86 0.01 <0.01 Moderate
Total CVD mortality 2 8,052 0.67 [0.45, 1.00] 64 0.09 0.05 Low
CHD incidence 1 1,000 0.48 [0.33, 0.71] - - <0.01 Low
CHD mortality 1 1,000 0.33 [0.13, 0.85] - - 0.02 Low
Stroke incidence 1 7,447 0.58 [0.42, 0.81] - - <0.01 Moderate
Stroke Mortality 0 - - - - - - - - - - - -
Myocardial infarction incidence 2 8,447 0.65 [0.49, 0.88] 50 0.16 <0.01 Moderate
Mycoardial infarction mortality 1 1,000 0.67 [0.31, 1.43] - - 0.30 Very low
Prospective cohorts
Total CVD incidence 8 53,508 0.88 [0.74, 1.03] 53 0.04 0.12 Very low
Total CVD mortality 21 883,878 0.79 [0.77, 0.82] 0 0.64 <0.01 Moderate
CHD incidence 7 88,632 0.73 [0.62, 0.86] 26 0.23 <0.01 Moderate
CHD mortality 6 270,565 0.73 [0.59, 0.89] 63 0.02 <0.01 Low
Stroke incidence 5 79,287 0.80 [0.71, 0.90] 0 0.63 <0.01 Low
Stroke Mortality 4 195,644 0.87 [0.80, 0.96] 0 0.74 <0.01 Very low
Myocardial infarction incidence 2 35,489 0.73 [0.61, 0.88] 0 0.66 <0.01 Very low
Mycoardial infarction mortality 0 - - - - - - - - - - - -
0
0.5
1
1.5
Benefit
Harm

Figure 2. Summary super-plot for the association between adherence to Mediterranean diet and CVD outcomes. N= Number of participants. Analyses were conducted using generic inverse variance random-effects models (≥ 5 trials available) or fixed effects models (<5 trials available). Interstudy heterogeneity was tested using the Cochran's Q statistic (Chi^2) at a significance level of P<0.10.